Funding
French Biotech AbTx Secures €1.7M Seed to Advance Miniaturised Cancer Antibodies
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
AbTx
Date
September 18, 2026
AbTx, a French biotech founded in 2024, secured €1.7 million (approximately $2 million) in a seed funding round from private and public investors. The company is developing precision therapies for solid tumors that have not responded to standard treatments.
The funding will support clinical development of its patented Therano-Stick platform, which uses enzymatic bio-conjugation to create miniaturized antibody-drug conjugates, or FDCs. AbTx also won the i-Lab award in September 2026, providing public validation alongside the funding.
AbTx is a seed-stage startup focused on oncology, specifically solid tumors. The company is based in France and is in an active growth phase, scaling its platform and preparing for clinical trials.
This development affects vendors serving early-stage biotech, including providers of lab informatics, CRO services, regulatory compliance tools, and clinical trial management software. AbTx's need for these solutions is likely to grow as it advances its pipeline.
The seed round and i-Lab award position AbTx to compete in the crowded antibody-drug conjugate market. The company's proprietary Therano-Stick platform differentiates it from other biotech firms, but the market remains highly competitive.
Monitor AbTx's progress in clinical development, particularly how quickly it moves its FDCs through the pipeline. The company's ability to secure partnerships or additional funding will be critical to its success.
For vendors, AbTx represents a potential customer in the early-stage biotech space. As the company scales, it will likely require specialized software and services, making it a target for outbound sales efforts.
Source:
VentureburnGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
